ZYC 200
Alternative Names: ZYC200Latest Information Update: 12 Mar 2008
At a glance
- Originator MGI Pharma Biologics
- Class Anti-inflammatories
- Mechanism of Action Immunosuppressants; Melanocyte-stimulating hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 08 Dec 2003 No development reported - Preclinical for Asthma in USA (unspecified route)
- 08 Dec 2003 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)
- 08 Dec 2003 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)